- AbbVie’s $1.73 quarterly dividend is supported by $17.8 billion in 2025 free cash flow versus $11.66 billion in dividends.
- Skyrizi and Rinvoq growth is helping offset Humira’s steep sales decline, supporting the outlook for ABBV dividends.
- A 2.70% forward yield, premium valuation and acquisition-related dilution raise the bar for new buyers.
Strong cash flow supports the payout, while valuation and post-Humira execution remain the central income-investor risks.
AbbVie (NYSE: ABBV) offers a quarterly dividend of $1.73 per share, or $6.92 annualized, translating into a 2.70% forward yield at a share price near $256.46. The stock is down 1.4% in the latest session but remains close to its 52-week high of $267.47.
For dividend investors, the key point is straightforward: the payout appears well funded today. But ABBV’s modest yield relative to its history, premium valuation and higher acquisition burden argue against chasing the shares aggressively.
Cash Flow Still Covers the Dividend
Free cash flow, rather than accounting earnings alone, is the clearest measure of AbbVie’s near-term dividend capacity.
AbbVie produced $17.8 billion in 2025 free cash flow against $11.66 billion of dividends, implying a free-cash-flow payout ratio in the mid-60% range. That is a reasonable cushion for a mature pharmaceutical company, leaving capital for research, debt service, acquisitions and future raises.
The company has returned roughly $62 billion to shareholders over five years, with dividends accounting for about $54 billion of that total. Its dividend-growth record also benefits from Abbott Laboratories’ pre-spin-off history, giving the combined lineage more than 50 consecutive years of increases.
Growth has slowed from the double-digit pace investors saw in earlier years. ABBV’s one-, three-, and five-year dividend growth rates are about 5.6%, 5.3%, and 6.1%, respectively, still solid but better described as moderate dividend growth than a high-growth income story.
Skyrizi and Rinvoq Must Replace Humira
AbbVie’s income outlook increasingly depends on whether its newer immunology medicines can sustain revenue growth.
Humira’s erosion remains severe after biosimilar competition, with sales falling 36.1% year over year in the second quarter. The offset has been encouraging: Skyrizi sales rose 24% to $5.5 billion and Rinvoq revenue increased nearly 24% to more than $2.5 billion.
Management’s important operating milestone is Skyrizi’s $21.7 billion full-year sales target. Meeting that goal would reinforce the case that AbbVie can fund continued mid-single-digit dividend growth despite Humira’s decline.
AbbVie also completed its $10.9 billion Apogee Therapeutics acquisition, expanding its immunology pipeline. However, the deal is expected to dilute adjusted EPS through 2027, adding execution and interest-cost risk before potential long-term benefits emerge.
Valuation Limits the Margin of Safety
The dividend looks dependable, but the current share price leaves less room for setbacks.
At roughly 72.5 times trailing earnings, ABBV trades well above its five-year median valuation. The current 2.70% yield also sits below its five-year average yield of 3.74%, suggesting the stock is not an obvious bargain for investors seeking maximum current income.
Bottom line ABBV remains a credible dividend-growth holding for investors who prioritize durable cash flow and healthcare exposure. Existing holders can reasonably hold and monitor free cash flow, Skyrizi sales and acquisition integration, while new income investors may prefer phased purchases or wait for a higher yield.
